4D Pharma Research Limited (SC336222): administration
- Status
- Administration ended
- Administration began
- 2023-03-17
- Administrators
- James Richard Clark, Blair Carnegie Nimmo
- Administrators' firm
- Interpath Advisory
- Formerly
- GT Biologics Limited; MM&S (5335) Limited
- Incorporated
- 2008-01-15
- Location
- Glasgow
- Industry
- 72110 Research and experimental development on biotechnology
Why it went into administration
- Parent or group failure
- Sustained trading losses
From the administrators' statement
4D Research and the rest of the 4D Group were a pharmaceutical group of companies developing LBPs, a novel class of drug derived from the human gut microbiome. The Group had a diverse pipeline of development programmes in several therapeutic areas, searching to treat a number of conditions including gastro-intestinal (IBS/IBD), immunooncology (pancreatic cancer, lung cancer, etc.) and respiratory (asthma) diseases. The Group launched several clinical trials, some of which were conducted in collaboration with key pharmaceutical industry players, such as MSD and Merck KGaA.
Most of the intellectual property in relation to the above sits within 4D Research, including several clinical stage drug candidates. 4D PLC, as the listed Parent company within the Group, was responsible for raising debt and equity funding for the Group, including 4D Research, given the Group was in drug development stage and hence prerevenue.
As at the date of the appointment, the Company employed 33 members of staff, most of whom are located at the Company’s leasehold premises in Aberdeen, with several staff also based in Leeds, using 4D Plc’s leasehold head office premises.
Administrators' statement of proposals (2023-04-27) · Companies House register